CN107583037A - 长效胰岛素制剂 - Google Patents

长效胰岛素制剂 Download PDF

Info

Publication number
CN107583037A
CN107583037A CN201710249012.1A CN201710249012A CN107583037A CN 107583037 A CN107583037 A CN 107583037A CN 201710249012 A CN201710249012 A CN 201710249012A CN 107583037 A CN107583037 A CN 107583037A
Authority
CN
China
Prior art keywords
insulin
study
subjects
insulin glargine
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710249012.1A
Other languages
English (en)
Chinese (zh)
Inventor
莱茵哈德·贝克
安克·弗里克
彼得·博德克
克里斯琴·富尔斯特
沃纳·米勒
凯特林·特奇
乌尔里克·沃纳
佩特拉·露丝
伊莎贝尔·舍特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107583037(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN107583037A publication Critical patent/CN107583037A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201710249012.1A 2010-05-19 2011-05-19 长效胰岛素制剂 Pending CN107583037A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP10305532.3 2010-05-19
EP10305532 2010-05-19
EP10305780 2010-07-13
EP10305780.8 2010-07-13
EP11305140.3 2011-02-10
EP11305140 2011-02-10
CN2011102251176A CN102319422A (zh) 2010-05-19 2011-05-19 长效胰岛素制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2011102251176A Division CN102319422A (zh) 2010-05-19 2011-05-19 长效胰岛素制剂

Publications (1)

Publication Number Publication Date
CN107583037A true CN107583037A (zh) 2018-01-16

Family

ID=44148980

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201410818149.0A Pending CN104622788A (zh) 2010-05-19 2011-05-19 长效胰岛素制剂
CN201710249012.1A Pending CN107583037A (zh) 2010-05-19 2011-05-19 长效胰岛素制剂
CN201710324824.8A Pending CN107583038A (zh) 2010-05-19 2011-05-19 长效胰岛素制剂
CN2011102251176A Withdrawn CN102319422A (zh) 2010-05-19 2011-05-19 长效胰岛素制剂
CN201410220537.9A Pending CN103948913A (zh) 2010-05-19 2011-05-19 长效胰岛素制剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201410818149.0A Pending CN104622788A (zh) 2010-05-19 2011-05-19 长效胰岛素制剂

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201710324824.8A Pending CN107583038A (zh) 2010-05-19 2011-05-19 长效胰岛素制剂
CN2011102251176A Withdrawn CN102319422A (zh) 2010-05-19 2011-05-19 长效胰岛素制剂
CN201410220537.9A Pending CN103948913A (zh) 2010-05-19 2011-05-19 长效胰岛素制剂

Country Status (44)

Country Link
US (11) US20110301081A1 ( )
EP (9) EP2387989B1 ( )
JP (5) JP5269945B2 ( )
KR (4) KR20170072960A ( )
CN (5) CN104622788A ( )
AR (1) AR081200A1 ( )
AU (1) AU2011202239C1 ( )
BR (2) BR122019006884B1 ( )
CA (1) CA2792669C ( )
CL (1) CL2012003197A1 ( )
CO (1) CO6640217A2 ( )
CR (1) CR20120578A ( )
CY (3) CY1115649T1 ( )
DK (3) DK2781212T3 ( )
DO (1) DOP2012000261A ( )
EC (1) ECSP12012298A ( )
ES (4) ES2676401T3 ( )
FI (1) FI2571517T4 ( )
GT (1) GT201200287A ( )
HK (4) HK1210435A1 ( )
HR (3) HRP20181028T2 ( )
HU (2) HUE039355T2 ( )
IL (2) IL221964A ( )
JO (2) JO2944B1 ( )
LT (2) LT2781212T ( )
MA (1) MA34224B1 ( )
MX (2) MX343489B ( )
MY (1) MY156188A ( )
NI (1) NI201200152A ( )
NZ (1) NZ602541A ( )
PE (2) PE20160781A1 ( )
PH (3) PH12012501895A1 ( )
PL (4) PL2387989T3 ( )
PT (3) PT2781212T ( )
RS (1) RS53559B1 ( )
RU (3) RU2564104C2 ( )
SG (2) SG10201510406YA ( )
SI (3) SI2781212T1 ( )
TN (1) TN2012000478A1 ( )
TR (2) TR201809475T4 ( )
TW (4) TWI496580B ( )
UY (1) UY33391A ( )
WO (1) WO2011144673A2 ( )
ZA (1) ZA201206998B ( )

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2505593A1 (en) 2005-12-28 2012-10-03 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
PL2229407T3 (pl) 2008-01-09 2017-06-30 Sanofi-Aventis Deutschland Gmbh Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
BRPI0919946A2 (pt) 2008-10-30 2016-02-16 Novo Nordisk As tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP5735960B2 (ja) * 2009-07-06 2015-06-17 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング メチオニンを含むインスリン製剤
CA2780460C (en) 2009-11-13 2018-09-04 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
BR112012011403B8 (pt) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2611458B1 (en) 2010-08-30 2016-09-21 Sanofi-Aventis Deutschland GmbH Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
BR112013018877A2 (pt) 2011-01-28 2016-10-04 Sanofi Sa composições farmacêuticas que compreendem anticorpos humanos para pcsk9
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
KR101810055B1 (ko) 2011-08-10 2017-12-18 아도시아 하나 이상의 유형의 기저 인슐린의 주사액
FR2984749A1 (fr) * 2011-12-23 2013-06-28 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 en combinaison avec une hormone gastro-intestinale a visee therapeutique
ES2550357T3 (es) 2011-08-29 2015-11-06 Sanofi-Aventis Deutschland Gmbh Combinación farmacéutica para su uso en el control glucémico en pacientes de diabetes de tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
TW201333870A (zh) * 2011-12-21 2013-08-16 艾登工具股份有限公司 決定病人胰島素療法的系統及方法
FR2985429B1 (fr) * 2012-01-09 2016-07-29 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle
EP2814461B1 (fr) 2012-01-09 2019-07-24 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
FR2985428B1 (fr) * 2012-01-09 2016-05-27 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
DE112013002122T5 (de) 2012-04-18 2014-12-31 Waters Technologies Corporation Verfahren zur Quantifizierung von Polypeptiden mittels Massenspektrometrie
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3001896B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
FR3001895B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
CN104994864B (zh) * 2012-12-19 2018-05-29 沃克哈特有限公司 包含人胰岛素或其类似物或衍生物的稳定水性组合物
HK1211231A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
CA2889162A1 (en) * 2012-12-26 2014-07-03 Wockhardt Limited Pharmaceutical composition
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
EP2976096B1 (en) * 2013-03-20 2019-02-27 Novo Nordisk A/S Insulin dosing regimen
RU2705797C2 (ru) * 2013-04-03 2019-11-12 Санофи Лечение сахарного диабета с помощью составов инсулинов длительного действия
US20220202711A1 (en) * 2013-04-03 2022-06-30 Sanofi Treatment of Diabetes Mellitus by Long-Acting Formulations of Insulins
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
HRP20190557T1 (hr) * 2013-06-17 2019-05-03 Sanofi-Aventis Deutschland Gmbh Formulacija s fiksnim omjerom inzulin glargin/liksisenatid
CN104587455A (zh) * 2013-10-31 2015-05-06 江苏万邦生化医药股份有限公司 一种胰岛素制剂
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080155A1 (en) 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
US9839692B2 (en) 2014-01-09 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2015104311A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
KR20160101195A (ko) 2014-01-09 2016-08-24 사노피 인슐린 아스파트의 안정화된 약제학적 제형
CN103830189A (zh) * 2014-03-04 2014-06-04 山东新时代药业有限公司 一种重组甘精胰岛素制剂及其制备方法
AR099937A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
TW201625605A (zh) 2014-04-04 2016-07-16 賽諾菲公司 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類
SG11201606619UA (en) 2014-04-04 2016-09-29 Sanofi Sa Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016001862A1 (en) 2014-07-04 2016-01-07 Wockhardt Limited Extended release formulations of insulins
JP2017528427A (ja) 2014-07-16 2017-09-28 サノフィ・バイオテクノロジー ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法
MX389178B (es) * 2014-12-12 2025-03-20 Sanofi Aventis Deutschland Formulacion de proporcion fija de insulina glargina/lixisenatida.
CN104688678B (zh) * 2015-02-05 2017-11-17 通化东宝药业股份有限公司 一种甘精胰岛素注射液的制备方法及其制备的甘精胰岛素注射液
CN104688677B (zh) * 2015-02-05 2018-02-09 通化东宝药业股份有限公司 一种稳定的甘精胰岛素注射液及其制备方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CA2995645A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
PT3229828T (pt) * 2015-11-10 2023-06-29 Sanofi Aventis Deutschland Formulação de razão fixa de insulina glargina/lixisenatido
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
CN105597087B (zh) * 2016-01-06 2019-04-26 山东新时代药业有限公司 一种甘精胰岛素注射液及其制备方法
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
WO2018055539A1 (en) 2016-09-22 2018-03-29 Wockhardt Limited Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue
TW201833132A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
WO2018115401A1 (en) 2016-12-22 2018-06-28 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
PL4019039T3 (pl) * 2017-07-27 2024-03-18 Adocia Kompozycje w postaci wodnego roztworu do wstrzykiwania zawierające co najmniej insulinę ludzką a21g i co najmniej jeden supresor glukagonu o działaniu posiłkowym
UY38249A (es) 2018-05-30 2019-12-31 Sanofi Sa Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico
WO2019243557A1 (en) 2018-06-21 2019-12-26 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
WO2019243628A1 (fr) 2018-06-22 2019-12-26 Adocia Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US20220233784A1 (en) 2019-05-29 2022-07-28 Sanofi Drug delivery device
JP7518149B2 (ja) 2019-07-12 2024-07-17 ノヴォ ノルディスク アー／エス 高濃度インスリン製剤
EP4069278B1 (en) * 2019-12-06 2025-06-11 Dr. Mary Morris & Associates, LLC Methods and compositions for the prevention of type 1 diabetes
US20230285583A1 (en) * 2020-05-22 2023-09-14 Hanmi Pharm. Co., Ltd. Liquid formulation of long-acting conjugate of glucagon, glp-1, and gip trigonal agonist
KR20230034356A (ko) 2020-07-02 2023-03-09 사노피 활성이 감소된 glp-1r 효능제 펩티드
CA3184546A1 (en) 2020-07-02 2022-01-06 Sanofi Glp-1r agonist / fgf21 fusion proteins
US20230302095A1 (en) * 2020-08-14 2023-09-28 Kyon Biotech Ag Increasing the efficacy of biological therapeutic molecules

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048783A1 (en) * 2002-06-18 2004-03-11 Aventis Pharma Deutschland Gmbh Acidic insulin preparations having improved stability
CN1635900A (zh) * 2001-08-28 2005-07-06 伊莱利利公司 Glp－1和基础胰岛素的预混合物
CN1898087A (zh) * 2003-12-22 2007-01-17 诺沃挪第克公司 用于储存药物液体的透明、柔性、不可渗透的塑料容器

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960702A (en) 1985-09-06 1990-10-02 Codon Methods for recovery of tissue plasminogen activator
PH23446A (en) 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
CH682806A5 (de) * 1992-02-21 1993-11-30 Medimpex Ets Injektionsgerät.
CH682805A5 (de) * 1992-02-24 1993-11-30 Medimpex Ets Anzeigeeinrichtung für ein Injektionsgerät.
CA2183577C (en) 1994-03-07 2007-10-30 John S. Patton Methods and compositions for pulmonary delivery of insulin
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
CO4750643A1 (es) 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
JP2001521006A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 不溶性インシュリン組成物
US6978471B1 (en) 1999-05-25 2005-12-20 Thomson Licensing S.A. System for acquiring and processing broadcast programs and program guide data
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
ES2310192T3 (es) 2000-09-18 2009-01-01 Sanos Bioscience A/S Uso de peptidos glp-2.
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US20030026872A1 (en) 2001-05-11 2003-02-06 The Procter & Gamble Co. Compositions having enhanced aqueous solubility and methods of their preparation
FR2827604B1 (fr) 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
US20100069293A1 (en) 2002-02-27 2010-03-18 Pharmain Corporation Polymeric carrier compositions for delivery of active agents, methods of making and using the same
US7115563B2 (en) 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
EP1525219B1 (en) 2002-07-04 2009-05-27 Zealand Pharma A/S Glp-1 and methods for treating diabetes
DE10235168A1 (de) 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
GB0309154D0 (en) 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
US7234933B2 (en) 2003-01-21 2007-06-26 Ortho-Tain, Inc. Dental appliance and method for reducing an amount of patient cooperation
GB0304822D0 (en) * 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
US7544656B2 (en) 2003-03-04 2009-06-09 The Technology Development Company, Ltd. Long acting injectable insulin composition and methods of making and using thereof
JP2007504167A (ja) 2003-08-29 2007-03-01 セントカー・インコーポレーテツド 抗組織因子抗体を用いる移植片の生存を向上する方法
EP1701714A2 (en) 2004-01-07 2006-09-20 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
US20080248999A1 (en) 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
KR20070004078A (ko) 2004-03-31 2007-01-05 센토코 인코포레이티드 인간 ｇｌｐ-1 모방체, 조성물, 방법 및 용도
SG158158A1 (en) 2004-12-22 2010-01-29 Centocor Inc Glp-1 agonists, compositions, methods and uses
US7879361B2 (en) 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
EP1945142B1 (en) 2005-09-26 2013-12-25 Medtronic, Inc. Prosthetic cardiac and venous valves
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
AU2006306241B9 (en) * 2005-10-24 2012-03-08 Nestec S.A. Dietary fiber formulation and method of administration
JP2009517410A (ja) 2005-11-30 2009-04-30 ジェネレクス ファーマシューティカルズ インコーポレイテッド 経口吸収される医薬製剤および投与方法
US20100029558A1 (en) 2005-12-06 2010-02-04 Bristow Cynthia L Alpha1 proteinase inhibitor peptides methods and use
CN101454019A (zh) * 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
EP2021368A4 (en) 2006-06-08 2010-01-20 Diabecore Medical Inc INSULIN OLIGOMERS DERIVED
DE102006031962A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
EP2076242B8 (en) * 2006-07-27 2013-02-20 Nektar Therapeutics Aerosolizable formulation comprising insulin for pulmonary delivery
EP2185689A2 (en) 2007-08-09 2010-05-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
EP2178909B1 (en) 2007-08-13 2015-10-21 Novo Nordisk A/S Rapid acting insulin analogues
MX2010005245A (es) 2007-11-16 2010-06-01 Novo Nordisk As Composiciones farmaceuticas que comprenden peptidos glp-1 o exendin-4 y un peptido de insulina basal.
US20090175840A1 (en) 2008-01-04 2009-07-09 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
WO2009104199A1 (en) 2008-02-19 2009-08-27 Biocon Limited A method of obtaining purified heterologous insulins expressed in yeast
JP2011523052A (ja) 2008-05-23 2011-08-04 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｌｐ−１受容体アゴニスト・バイオアッセイ
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
WO2010028055A1 (en) 2008-09-02 2010-03-11 Biodel, Inc. Insulin with a basal release profile
DE102008053048A1 (de) * 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
BRPI0919946A2 (pt) 2008-10-30 2016-02-16 Novo Nordisk As tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente
EA029759B1 (ru) 2009-02-13 2018-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
US8709400B2 (en) 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
CA2769540C (en) * 2009-07-31 2017-08-15 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
CA2780460C (en) 2009-11-13 2018-09-04 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
US20110118178A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
US20110118180A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
BR112012011403B8 (pt) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
PL2329848T5 (pl) 2009-11-13 2019-12-31 Sanofi-Aventis Deutschland Gmbh Liksysenatyd z insuliną glargine i metforminą jako terapia skojarzona do leczenia cukrzycy typu 2
CN102933200B (zh) 2009-12-18 2015-11-25 莱迪杜德制药公司 包含磷脂的单相凝胶组合物
JP2013520175A (ja) 2010-02-22 2013-06-06 ケース ウェスタン リザーブ ユニバーシティ 可溶形および結晶形の長時間作用型インスリン類似体製剤
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
AR080884A1 (es) 2010-04-14 2012-05-16 Sanofi Aventis Conjugados de insulina-sirna
US8637458B2 (en) 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2011144674A2 (en) 2010-05-20 2011-11-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
US9085757B2 (en) 2010-06-17 2015-07-21 Regents Of The University Of Minnesota Production of insulin producing cells
US8532933B2 (en) 2010-06-18 2013-09-10 Roche Diagnostics Operations, Inc. Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
EP2611458B1 (en) 2010-08-30 2016-09-21 Sanofi-Aventis Deutschland GmbH Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
RS59423B1 (sr) 2010-10-27 2019-11-29 Novo Nordisk As Lečenje dijabetesa melitusa korišćenjem insulinskih injekcija davanih u različitim intervalima ubrizgavanja
WO2012065996A1 (en) 2010-11-15 2012-05-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND MALTOSYL-ß-CYCLODEXTRIN
WO2012066086A1 (en) 2010-11-17 2012-05-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN
CA2825162A1 (en) 2011-02-02 2012-08-09 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
EP2683406B1 (en) 2011-03-11 2019-05-08 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
WO2013050378A1 (en) 2011-10-04 2013-04-11 Sanofi-Aventis Deutschland Gmbh Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1635900A (zh) * 2001-08-28 2005-07-06 伊莱利利公司 Glp－1和基础胰岛素的预混合物
US20040048783A1 (en) * 2002-06-18 2004-03-11 Aventis Pharma Deutschland Gmbh Acidic insulin preparations having improved stability
CN1898087A (zh) * 2003-12-22 2007-01-17 诺沃挪第克公司 用于储存药物液体的透明、柔性、不可渗透的塑料容器

Also Published As

Publication number Publication date
US20200384087A1 (en) 2020-12-10
KR20140109515A (ko) 2014-09-15
RU2564104C2 (ru) 2015-09-27
TW201607552A (zh) 2016-03-01
EP2387989A3 (en) 2012-04-18
ES2676401T3 (es) 2018-07-19
HK1210435A1 (en) 2016-04-22
RU2015132860A (ru) 2017-02-09
TW201208695A (en) 2012-03-01
TWI496580B (zh) 2015-08-21
HK1198428A1 (en) 2015-04-24
EP3607935A1 (en) 2020-02-12
FI2571517T4 (fi) 2024-09-20
US9345750B2 (en) 2016-05-24
EP2571517B9 (en) 2024-10-16
EP2571517A2 (en) 2013-03-27
KR20170072960A (ko) 2017-06-27
EP2387989A2 (en) 2011-11-23
DK2571517T3 (en) 2018-07-23
IL221964A (en) 2017-04-30
ES2509943T3 (es) 2014-10-20
HRP20140860T1 (hr) 2014-10-24
JP2015172068A (ja) 2015-10-01
CY1115649T1 (el) 2017-01-04
ECSP12012298A (es) 2012-12-28
RU2017146048A (ru) 2019-06-27
CN102319422A (zh) 2012-01-18
EP3636250A1 (en) 2020-04-15
MX343489B (es) 2016-11-08
PH12015501421B1 (en) 2015-09-07
TWI469787B (zh) 2015-01-21
KR20130040824A (ko) 2013-04-24
MA34224B1 (fr) 2013-05-02
EP4218723A3 (en) 2023-11-08
GT201200287A (es) 2015-03-09
TW201735941A (zh) 2017-10-16
KR101989343B1 (ko) 2019-06-14
UY33391A (es) 2011-10-31
CN107583038A (zh) 2018-01-16
DK2387989T3 (da) 2014-10-20
SG185593A1 (en) 2012-12-28
PE20130511A1 (es) 2013-05-02
EP3824876A1 (en) 2021-05-26
JP2020040990A (ja) 2020-03-19
HK1202428A1 (en) 2015-10-02
EP2781212A1 (en) 2014-09-24
HUE039354T2 (hu) 2018-12-28
PT2571517T (pt) 2018-07-10
JP2018044003A (ja) 2018-03-22
CR20120578A (es) 2013-03-04
EP2571517B2 (en) 2024-06-19
EP2387989B1 (en) 2014-07-16
HK1248592A1 (zh) 2018-10-19
JO2944B1 (en) 2016-03-15
SG10201510406YA (en) 2016-01-28
US20200215163A1 (en) 2020-07-09
SI2571517T1 (en) 2018-08-31
HRP20181028T1 (hr) 2018-08-24
ES2690302T5 (es) 2024-12-03
DOP2012000261A (es) 2013-01-31
MY156188A (en) 2016-01-29
IL251318B (en) 2018-12-31
US20150164999A1 (en) 2015-06-18
ES2690302T3 (es) 2018-11-20
CO6640217A2 (es) 2013-03-22
HK1248593A1 (zh) 2018-10-19
LT2571517T (lt) 2018-07-25
JP6333775B2 (ja) 2018-05-30
WO2011144673A3 (en) 2012-05-03
CA2792669A1 (en) 2011-11-24
PL2571517T5 (pl) 2024-12-02
PH12012501895A1 (en) 2016-02-03
EP4218723A2 (en) 2023-08-02
TWI605825B (zh) 2017-11-21
HRP20181028T4 (hr) 2024-09-27
HRP20181026T1 (hr) 2018-08-24
SI2387989T1 (sl) 2014-10-30
MX2019003693A (es) 2019-07-04
CN104622788A (zh) 2015-05-20
TW201427684A (zh) 2014-07-16
BR112012029131A2 (pt) 2016-09-13
EP3824876B1 (en) 2023-02-22
ES2945208T3 (es) 2023-06-29
US20140206611A1 (en) 2014-07-24
CY1120407T1 (el) 2019-07-10
AU2011202239A1 (en) 2011-12-08
RU2642662C2 (ru) 2018-01-25
EP3824876B8 (en) 2023-08-02
DK2571517T4 (da) 2024-09-23
JP2011241213A (ja) 2011-12-01
JOP20150245B1 (ar) 2021-08-17
PH12015501421A1 (en) 2015-09-07
PL2781212T3 (pl) 2018-08-31
PL3824876T3 (pl) 2024-02-19
LT2781212T (lt) 2018-07-25
BR112012029131B1 (pt) 2020-03-10
PL2387989T3 (pl) 2014-12-31
TN2012000478A1 (en) 2014-04-01
PE20160781A1 (es) 2016-08-26
US20210308225A1 (en) 2021-10-07
BR122019006884B1 (pt) 2022-08-23
EP2571517B1 (en) 2018-04-04
RU2017146048A3 ( ) 2021-07-01
CL2012003197A1 (es) 2013-01-25
PH12019500517A1 (en) 2020-03-02
MX2012011278A (es) 2012-11-06
NI201200152A (es) 2013-01-24
US20160228516A1 (en) 2016-08-11
CA2792669C (en) 2015-09-29
NZ602541A (en) 2013-11-29
PT2781212T (pt) 2018-07-10
RU2011119988A (ru) 2012-11-27
KR101486743B1 (ko) 2015-01-28
EP2781212B1 (en) 2018-04-04
TR201809475T4 (tr) 2018-07-23
DK2781212T3 (en) 2018-07-23
EP3424491A1 (en) 2019-01-09
IL251318A0 (en) 2017-05-29
US20110301081A1 (en) 2011-12-08
AU2011202239C1 (en) 2017-03-16
US20160339084A1 (en) 2016-11-24
US20190388511A1 (en) 2019-12-26
US20120122774A1 (en) 2012-05-17
PT2387989E (pt) 2014-09-15
SI2571517T2 (sl) 2024-10-30
ZA201206998B (en) 2013-05-29
MX389052B (es) 2025-03-20
ES2690302T9 (en) 2025-01-02
SI2781212T1 (en) 2018-08-31
WO2011144673A2 (en) 2011-11-24
KR20180088752A (ko) 2018-08-06
JP2013147509A (ja) 2013-08-01
RS53559B1 (en) 2015-02-27
CN103948913A (zh) 2014-07-30
HRP20181028T2 (hr) 2025-01-03
JP5269945B2 (ja) 2013-08-21
KR101913672B1 (ko) 2018-11-01
AR081200A1 (es) 2012-07-04
TR201809514T4 (tr) 2018-07-23
CY1121042T1 (el) 2019-12-11
HUE039355T2 (hu) 2018-12-28
AU2011202239B2 (en) 2012-06-07
PL2571517T3 (pl) 2018-09-28
EP3400931A1 (en) 2018-11-14
US20190046616A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
US20210308225A1 (en) Long-Acting Formulations of Insulin
HK40041529A (en) Long-acting formulations of insulins
AU2012216648B2 (en) Long-acting formulations of insulins
HK40023504A (en) Long - acting formulations of insulins
HK1260174A1 (en) Long - acting formulations of insulins
HK1202428B (en) Long-acting formulations of insulins
AU2014203421A1 (en) Long-acting formulations of insulins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1248593

Country of ref document: HK

CB02 Change of applicant information

Address after: Fa Guobali

Applicant after: Sanofi

Address before: Fa Guobali

Applicant before: SANOFI-AVENTIS

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20210715

Address after: Frankfurt, Germany

Applicant after: SANOFI-AVENTIS DEUTSCHLAND GmbH

Address before: Fa Guobali

Applicant before: Sanofi

TA01 Transfer of patent application right